POTOMAC, Md. - IGC Pharma, Inc. (NYSE American: IGC) has initiated a Phase 2b clinical trial through ClinCloud, a Florida-based clinical research facility, to evaluate the safety and efficacy of IGC-AD1, a drug aimed at treating agitation in Alzheimer’s patients. The first patient has been dosed, marking a significant step in the development of this potential treatment.
IGC-AD1 is being investigated for its dual mechanism of action, which includes the properties of a CB1 receptor partial agonist and an inflammasome inhibitor. The trial is being conducted across twelve sites in the United States and Canada, with ClinCloud operating two of these sites in Maitland and Viera-Melbourne, Florida.
Jessica Branning, founder of ClinCloud, emphasized the need for new treatments for agitation in Alzheimer's, a symptom affecting a significant portion of patients. She expressed hope that IGC-AD1 could improve the quality of life for those suffering from the disease. Ram Mukunda, CEO of IGC Pharma, shared his optimism about the trial's expansion, which aims to bolster data collection and diversify the patient population.
The trial plans to enroll 146 patients, with half receiving IGC-AD1 and the other half a placebo. IGC Pharma is on track to open additional trial sites in the U.S. and Canada to ensure a representative sample of participants, including underrepresented populations.
IGC Pharma's portfolio focuses on addressing Alzheimer's disease through various therapeutic angles, including neuroinflammation, beta-amyloid plaques, and neurofibrillary tangles. The company is also engaged in Generative AI projects to support clinical trials, early detection, and drug interactions with cannabinoids.
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.